Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis

E. A. Akriviadis, H. Steindel, P. C. Pinto, T. L. Fong, G. Kanel, T. B. Reynolds, Sanjeev Gupta

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Colchicine treatment was used in this randomized placebo-controlled trial in patients with severe acute alcoholic hepatitis [serum bilirubin ≥ 5 mg/dL (85.5 μmol/L) mean, 17.5 ± 7.5 mg/dL (299.25 ± 128.25 μmol/L)]. Hospitalization mortality and morbidity and the effect on biochemical test results were the end points of the treatment. Patients in the two groups were evenly matched by demographics and laboratory test results. Mean time to study entry was < 7 days from admission. The duration of the trial was 30 days. Thirty-six patients (24 men, 12 women) received colchicine (1 mg orally every morning) and 36 (25 men, 11 women) received an identical placebo. Seven (19%) colchicine-treated and six (17%) control patients died during the index hospitalization after a mean of 17.4 ± 10.8 and 17.8 ± 5.3 days, respectively (NS). During a 4-month follow-up period from entry into the trial, there were two additional deaths in each group. No differences between placebo- and colchicine-treated patients were observed in any of the laboratory parameters (serum bilirubin, aspartate transaminase, alanine transaminase, prothrombin activity, albumin, white blood cell count, hemoglobin, and creatinine) that were followed up over the 30-day treatment period. The frequency of complications did not differ statistically between the two groups. This study showed no effect of colchicine treatment on mortality and morbidity of severe alcoholic hepatitis. Colchicine cannot be recommended for the treatment of patients with alcoholic hepatitis.

Original languageEnglish (US)
Pages (from-to)811-818
Number of pages8
JournalGastroenterology
Volume99
Issue number3
StatePublished - 1990
Externally publishedYes

Fingerprint

Alcoholic Hepatitis
Colchicine
Survival
Placebos
Bilirubin
Hospitalization
Morbidity
Therapeutics
Mortality
Prothrombin
Aspartate Aminotransferases
Serum
Alanine Transaminase
Leukocyte Count
Albumins
Creatinine
Hemoglobins
Randomized Controlled Trials
Demography

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Akriviadis, E. A., Steindel, H., Pinto, P. C., Fong, T. L., Kanel, G., Reynolds, T. B., & Gupta, S. (1990). Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology, 99(3), 811-818.

Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. / Akriviadis, E. A.; Steindel, H.; Pinto, P. C.; Fong, T. L.; Kanel, G.; Reynolds, T. B.; Gupta, Sanjeev.

In: Gastroenterology, Vol. 99, No. 3, 1990, p. 811-818.

Research output: Contribution to journalArticle

Akriviadis, EA, Steindel, H, Pinto, PC, Fong, TL, Kanel, G, Reynolds, TB & Gupta, S 1990, 'Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis', Gastroenterology, vol. 99, no. 3, pp. 811-818.
Akriviadis EA, Steindel H, Pinto PC, Fong TL, Kanel G, Reynolds TB et al. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology. 1990;99(3):811-818.
Akriviadis, E. A. ; Steindel, H. ; Pinto, P. C. ; Fong, T. L. ; Kanel, G. ; Reynolds, T. B. ; Gupta, Sanjeev. / Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. In: Gastroenterology. 1990 ; Vol. 99, No. 3. pp. 811-818.
@article{2c5cc08e70464ee9b667b90a28a8fb4c,
title = "Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis",
abstract = "Colchicine treatment was used in this randomized placebo-controlled trial in patients with severe acute alcoholic hepatitis [serum bilirubin ≥ 5 mg/dL (85.5 μmol/L) mean, 17.5 ± 7.5 mg/dL (299.25 ± 128.25 μmol/L)]. Hospitalization mortality and morbidity and the effect on biochemical test results were the end points of the treatment. Patients in the two groups were evenly matched by demographics and laboratory test results. Mean time to study entry was < 7 days from admission. The duration of the trial was 30 days. Thirty-six patients (24 men, 12 women) received colchicine (1 mg orally every morning) and 36 (25 men, 11 women) received an identical placebo. Seven (19{\%}) colchicine-treated and six (17{\%}) control patients died during the index hospitalization after a mean of 17.4 ± 10.8 and 17.8 ± 5.3 days, respectively (NS). During a 4-month follow-up period from entry into the trial, there were two additional deaths in each group. No differences between placebo- and colchicine-treated patients were observed in any of the laboratory parameters (serum bilirubin, aspartate transaminase, alanine transaminase, prothrombin activity, albumin, white blood cell count, hemoglobin, and creatinine) that were followed up over the 30-day treatment period. The frequency of complications did not differ statistically between the two groups. This study showed no effect of colchicine treatment on mortality and morbidity of severe alcoholic hepatitis. Colchicine cannot be recommended for the treatment of patients with alcoholic hepatitis.",
author = "Akriviadis, {E. A.} and H. Steindel and Pinto, {P. C.} and Fong, {T. L.} and G. Kanel and Reynolds, {T. B.} and Sanjeev Gupta",
year = "1990",
language = "English (US)",
volume = "99",
pages = "811--818",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis

AU - Akriviadis, E. A.

AU - Steindel, H.

AU - Pinto, P. C.

AU - Fong, T. L.

AU - Kanel, G.

AU - Reynolds, T. B.

AU - Gupta, Sanjeev

PY - 1990

Y1 - 1990

N2 - Colchicine treatment was used in this randomized placebo-controlled trial in patients with severe acute alcoholic hepatitis [serum bilirubin ≥ 5 mg/dL (85.5 μmol/L) mean, 17.5 ± 7.5 mg/dL (299.25 ± 128.25 μmol/L)]. Hospitalization mortality and morbidity and the effect on biochemical test results were the end points of the treatment. Patients in the two groups were evenly matched by demographics and laboratory test results. Mean time to study entry was < 7 days from admission. The duration of the trial was 30 days. Thirty-six patients (24 men, 12 women) received colchicine (1 mg orally every morning) and 36 (25 men, 11 women) received an identical placebo. Seven (19%) colchicine-treated and six (17%) control patients died during the index hospitalization after a mean of 17.4 ± 10.8 and 17.8 ± 5.3 days, respectively (NS). During a 4-month follow-up period from entry into the trial, there were two additional deaths in each group. No differences between placebo- and colchicine-treated patients were observed in any of the laboratory parameters (serum bilirubin, aspartate transaminase, alanine transaminase, prothrombin activity, albumin, white blood cell count, hemoglobin, and creatinine) that were followed up over the 30-day treatment period. The frequency of complications did not differ statistically between the two groups. This study showed no effect of colchicine treatment on mortality and morbidity of severe alcoholic hepatitis. Colchicine cannot be recommended for the treatment of patients with alcoholic hepatitis.

AB - Colchicine treatment was used in this randomized placebo-controlled trial in patients with severe acute alcoholic hepatitis [serum bilirubin ≥ 5 mg/dL (85.5 μmol/L) mean, 17.5 ± 7.5 mg/dL (299.25 ± 128.25 μmol/L)]. Hospitalization mortality and morbidity and the effect on biochemical test results were the end points of the treatment. Patients in the two groups were evenly matched by demographics and laboratory test results. Mean time to study entry was < 7 days from admission. The duration of the trial was 30 days. Thirty-six patients (24 men, 12 women) received colchicine (1 mg orally every morning) and 36 (25 men, 11 women) received an identical placebo. Seven (19%) colchicine-treated and six (17%) control patients died during the index hospitalization after a mean of 17.4 ± 10.8 and 17.8 ± 5.3 days, respectively (NS). During a 4-month follow-up period from entry into the trial, there were two additional deaths in each group. No differences between placebo- and colchicine-treated patients were observed in any of the laboratory parameters (serum bilirubin, aspartate transaminase, alanine transaminase, prothrombin activity, albumin, white blood cell count, hemoglobin, and creatinine) that were followed up over the 30-day treatment period. The frequency of complications did not differ statistically between the two groups. This study showed no effect of colchicine treatment on mortality and morbidity of severe alcoholic hepatitis. Colchicine cannot be recommended for the treatment of patients with alcoholic hepatitis.

UR - http://www.scopus.com/inward/record.url?scp=0025333893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025333893&partnerID=8YFLogxK

M3 - Article

C2 - 2199290

AN - SCOPUS:0025333893

VL - 99

SP - 811

EP - 818

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 3

ER -